| Bioactivity | Aganepag is a potent Prostanoid EP2 receptor agonist, with an EC50 of 0.19 nM, and shows no activity at EP4 receptor. Aganepag can be used in the research of wound healing, scar reduction, scar prevention and wrinkle treatment and prevention. | ||||||||||||
| Invitro | Aganepag (Compound 3) is a potent Prostanoid EP2 receptor agonist, with an EC50 of 0.19 nM, and shows no activity at EP4. Aganepag can be used in the research of wound healing, scar reduction, scar prevention and wrinkle treatment and prevention[1]. | ||||||||||||
| Name | Aganepag | ||||||||||||
| CAS | 910562-18-4 | ||||||||||||
| Formula | C24H31NO4S | ||||||||||||
| Molar Mass | 429.57 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Robert M. Burk, et al. Compounds and methods for skin repair. WO2014078434A1 |